ストックスクリーナーアプリを入手
21.43
6.56%
1.32
プレマーケット:
20.99
-0.44
-2.05%
前日終値:
$20.11
開ける：
$20.29
24時間の取引高:
127.48K
Relative Volume:
0.46
時価総額：
$665.75M
収益：
-
当期純損益:
$-49.81M
株価収益率:
-9.9397
EPS:
-2.156
ネットキャッシュフロー:
$-42.93M
1週間 パフォーマンス:
+12.85%
1か月 パフォーマンス:
+42.87%
6か月 パフォーマンス:
+510.54%
1年 パフォーマンス:
+589.07%
1日の値動き範囲:
$19.53
$21.57
1週間の範囲:
$18.42
$21.57
52週間の値動き範囲:
$1.60
$21.57
Alto Neuroscience Inc Stock (ANRO) Company Profile
名前
Alto Neuroscience Inc
セクター
電話
773-255-5012
住所
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
21.43 | 624.74M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | 再開されました | Chardan Capital Markets | Buy |
| 2025-11-17 | 開始されました | BTIG Research | Buy |
| 2025-09-29 | 開始されました | Chardan Capital Markets | Buy |
| 2024-10-23 | ダウングレード | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-09-03 | 開始されました | Wedbush | Outperform |
| 2024-02-27 | 開始されました | Jefferies | Buy |
| 2024-02-27 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-27 | 開始されました | Stifel | Buy |
| 2024-02-27 | 開始されました | TD Cowen | Outperform |
| 2024-02-27 | 開始されました | William Blair | Outperform |
すべてを表示
Alto Neuroscience Inc (ANRO) 最新ニュース
Alto Neuroscience Stock Quote, Share Price, News and Analysis - Longbridge
Alto Neuroscience (NASDAQ: ANRO) CEO has shares withheld for taxes - Stock Titan
Alto Neuroscience (ANRO) CFO reports 2,806-share tax withholding - Stock Titan
ANRO: ALTO-207 and ALTO-101 advance with biomarker-driven trials and improved formulations for mental health - TradingView
VSE Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday - Intellectia AI
Alto Neuroscience (NYSE:ANRO) Sets New 52-Week HighShould You Buy? - MarketBeat
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders - Benzinga
ARMISTICE CAPITAL, LLC Reduces Stake in Alto Neuroscience Inc - GuruFocus
March Presentations to Spotlight Alto Neuroscience's Clinical Strategy - AD HOC NEWS
Alto Neuroscience Announces Participation in Upcoming Investor Conferences - The Joplin Globe
Alto Neuroscience, Inc. (NYSE:ANRO) Slides in Biotech Indices - Kalkine Media
Alto Neuroscience (NYSE:ANRO) Trading Down 6.6%What's Next? - MarketBeat
Alto Neuroscience (NYSE:ANRO) Trading Up 10%Here's What Happened - MarketBeat
Vestal Point reports 8% stake in Alto Neuroscience (ANRO) - Stock Titan
ANRO: BTIG Analyst Maintains 'Buy' Rating, Raises Price Target t - GuruFocus
ANRO: BTIG Analyst Maintains 'Buy' Rating, Raises Price Target to $28 | ANRO Stock News - GuruFocus
Market Overview: Can Alto Neuroscience Inc expand into new marketsPortfolio Gains Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Alto Neuroscience completes enrollment in schizophrenia drug trial By Investing.com - Investing.com Australia
Alto Neuroscience completes enrollment in schizophrenia drug trial - Investing.com South Africa
Analysts Are Bullish on Top Healthcare Stocks: Grace Therapeutics (GRCE), Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia - BioSpace
What are Alto Neuroscience Inc.’s recent SEC filings showing2025 Earnings Impact & Capital Efficient Trading Techniques - mfd.ru
Is Alto Neuroscience Inc. stock attractive after correctionPortfolio Performance Summary & AI Enhanced Trading Alerts - mfd.ru
Alto Neuroscience (NYSE:ANRO) Trading 9.8% HigherShould You Buy? - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Alto Neuroscience, Inc.'s (NYSE:ANRO) Intrinsic Value Is Potentially 58% Above Its Share Price - Yahoo Finance
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - BioSpace
Alto Neuroscience announces $75 million ATM offering - MSN
Aug Volume: Can Andretti Acquisition Corp. II Equity Warrant maintain its current growth rate2025 Breakouts & Breakdowns & Consistent Return Strategy Ideas - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Context Therapeutics (CNTX) and Connect Biopharma Holdings (CNTB) - The Globe and Mail
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Short Interest in Alto Neuroscience, Inc. (NYSE:ANRO) Drops By 21.0% - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Analyst Calls: What chart patterns are forming on VNOPRNTrade Signal Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Alto Neuroscience receives patent for depression treatment method By Investing.com - Investing.com Nigeria
Alto Neuroscience issued patent for ALTO-207 - TipRanks
Alto Neuroscience Granted Patent for New Method of Treating Depression With ALTO-207 - marketscreener.com
Alto Neuroscience receives patent for depression treatment method - Investing.com
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression - Business Wire
Short Squeeze: Can Alto Neuroscience Inc stock deliver strong Q4 earningsPortfolio Gains Summary & Reliable Price Breakout Signals - Bộ Nội Vụ
Alto Neuroscience, Inc. Presents New Data At the 64Th Annual Meeting of the American College of Neuropsychopharmacology - marketscreener.com
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology - Business Wire
Chart Watch: Will Alto Neuroscience Inc stock test record highs in 2025Weekly Trade Review & AI Optimized Trade Strategies - Bộ Nội Vụ
Alto Neuroscience (NYSE:ANRO) Trading Up 8.1% – Should You Buy? - Defense World
Does Alto Neuroscience Inc. stock trade at a discount to peers2025 Retail Activity & Step-by-Step Trade Execution Guides - Улправда
What margin trends mean for Alto Neuroscience Inc. stockDividend Hike & Trade Opportunity Analysis - Улправда
Alto Neuroscience (NYSE:ANRO) Stock Price Up 8.1%What's Next? - MarketBeat
Why Alto Neuroscience Inc. stock could be next big winner2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - Улправда
How Alto Neuroscience Inc. stock performs in stagflationSell Signal & Consistent Profit Trading Strategies - Улправда
Is Alto Neuroscience Inc. stock bottoming after sell offWeekly Market Report & Consistent Income Trade Ideas - Улправда
Alto Neuroscience Inc (ANRO) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):